



SPORTSCARDIOLOGYBC

# Cardiovascular Risk Factors and Primary Prevention in Athletes

Dr. James McKinney, M.D., FRCP(C)

Sports Medicine Rounds

January 6<sup>th</sup> 2016



SPORTSCARDIOLOGYBC

# Disclosures

- Cardiac risk factors are NOT exciting
- Not a lot is known about the CV risk profile of athletes
- No one is going to give you a:



For starting a medication or recommending health behaviour change(s)



# T/F – CVD is the number cause of death in Canada



SPORTSCARDIOLOGYBC

## Leading causes of death, by sex (Both sexes)

	2011		
	Both sexes		
	rank	number	%
<b>Total, all causes of death</b>	...	<b>242,074</b>	<b>100.0</b>
Malignant neoplasms (cancer)	1	72,476	29.9
Diseases of heart (heart disease)	2	47,627	19.7
Cerebrovascular diseases (stroke)	3	13,283	5.5
Chronic lower respiratory diseases	4	11,184	4.6
Accidents (unintentional injuries)	5	10,716	4.4
Diabetes mellitus (diabetes)	6	7,194	3.0
Alzheimer's disease	7	6,356	2.6
Influenza and pneumonia	8	5,767	2.4
Intentional self-harm (suicide)	9	3,728	1.5
Nephritis, nephrotic syndrome and nephrosis (kidney disease)	10	3,294	1.4

**FALSE!!!**

**Notes:** Causes of death are coded to the 10th revision of the World Health Organization's International Statistical Classification of Diseases and Related Health Problems (ICD-10).

**Sources:** Statistics Canada, CANSIM table [102-0561](#).

Last modified: 2014-01-28.

For more information, consult [Health in Canada](#).

# T/F – CVD is the number cause of death worldwide



SPORTSCARDIOLOGYBC

Globally, 1 in 3 deaths will be caused by CVD



**TRUE!!!!**

# Primary Prevention



SPORTSCARDIOLOGYBC

- Primary prevention focuses on the modification of known risk factors
- Is aimed at preventing the clinical manifestations of CVD
  - such as myocardial infarction (MI) and stroke
- Primary prevention is paramount for the large number of individuals who are at high risk for CVD

# What is Ideal Cardiovascular Health?

- The absence of cardiovascular disease
- A healthy lifestyle
  - (sufficient exercise, a healthy diet, absence of smoking, and BMI , 25 kg/m<sup>2</sup>)
  - Ideal health factors (untreated normal values of blood pressure, cholesterol, and fasting glucose)
- These parameters, termed ‘**Life’s Simple 7**’, are presented in an AHA educational site, [mylifecheck.org](http://mylifecheck.org)



# The Simple 7 – Primordial Prevention

- Cigarette smoking: nonsmoking is ideal
- Physical activity:  $\geq 150$  min moderate intensity or equivalent exercise per week is ideal
- BMI:  $< 25 \text{ kg/m}^2$  is ideal
- Healthy diet: achieving at least four of the five important dietary components, focusing on fruits and vegetables, fish, fibre, and sodium intake and sweetened beverage intake
- Total cholesterol level:  $< 200 \text{ mg/dl}$  is ideal in adults,  $< 170 \text{ mg/dl}$  is ideal in children
- Blood pressure:  $< 120/80 \text{ mmHg}$  is ideal
- Fasting plasma glucose level:  $< 100 \text{ mg/dl}$  is ideal

# What % of American adults have >5 of 7 of the 'simple 7'

- A – 10%
- B – 20%
- C – 30%
- D – 40%
- E – 50%



SPORTSCARDIOLOGYBC

# What % of American adults have >5 of 7 of the 'simple 7'

- A – 10%
- **B – 20%**
- C – 30%
- D – 40%
- E – 50%





Only 40% of children  $>5/7$   
of the simple 7



SPORTSCARDIOLOGYBC



# What is a risk factor?



SPORTSCARDIOLOGYBC

- A risk factor is a characteristic or feature of an individual or population that presents early in life and associates with an increased risk of developing future disease
- To have clinical usefulness, it must predate the onset of clinical disease
- The risk marker of interest may be an:
  - acquired behavior (e.g., smoking)
  - an inherited trait (e.g., familial hyperlipidemia)
  - a laboratory value (e.g. LDL)
  - an exposure (radiation)
  - a location (Chernobyl)

# What is a risk factor?



SPORTSCARDIOLOGYBC

## Factors of Risk in the Development of Coronary Heart Disease— Six-Year Follow-up Experience

### The Framingham Study

WILLIAM B. KANNEL, M.D., THOMAS R. DAWBER, M.D., F.A.C.P.,  
ABRAHAM KAGAN, M.D., F.A.C.P., NICHOLAS REVOTSKIE, M.D.,  
AND JOSEPH STOKES, III, M.D.  
*Framingham, Massachusetts*



Thomas Dawber, M.D.

- The term “**risk factor**” was popularized in the medical lexicon by Dawber and Kannel in their 1961 publication



# Who are these people?

SPORTSCARDIOLOGYBC



# True or False? The smoker died first?







# True or False? The smoker died first



# True or False? The person with the highest CAD risk died first?



## Death and aftermath

Stalin's health deteriorated towards the end of World War II. He suffered from [atherosclerosis](#) from his heavy smoking. He suffered a mild stroke around the time of the Victory Parade, and a severe heart attack in October 1945.<sup>[308]</sup>





# Framingham



- What is it?
- How old is it?
- Has it taught us anything? What?



## **Framingham Heart Study**

A Project of the National Heart, Lung, and Blood Institute and Boston University

# This is Framingham



SPORTSCARDIOLOGYBC




# FDR



SPORTSCARDIOLOGYBC

- Franklin D Roosevelt, the war-time President of the USA from 1933 to 1945
- 1932 - his blood pressure was 140/100 mm Hg
- President chose an ENT as his personal physician
- 1935 and 1941, FDR's BP rose from 136/78 to 188/105
- "no more than normal for a man of his age" -ENT doc



# Howard G Bruenn



SPORTSCARDIOLOGYBC

- FDR - admitted for dyspnea on exertion, diaphoresis, and abdominal distension
- Cardiologist Howard G Bruenn, noted “blood pressure 186/108” and a chest radiograph showing an “increase in size of the cardiac shadow”
- The young cardiologist gave Roosevelt his first diagnosis of “hypertension, hypertensive heart disease, and cardiac failure”
- Bruenn had few therapeutic options to provide, and suggested digitalis and reduction of salt intake
- CXR 2 wks later showed decr heart size





# ROOSEVELT DEAD!

## Cerebral Hemorrhage Proves Fatal; President Truman Sworn in Office

Yanks Near  
Suburb Area  
of Berlin

Times Staff Writer  
and Editor W.H.  
Rosenberg Write From

APRIL 12, 1945  
The news of the death of President Franklin D. Roosevelt, which came at 1:05 p.m. today, was a shock to the American people. The President had been in poor health for some time, and his death was expected by many. The news of his death was a great loss to the country.



### Emergency Cabinet Session Summoned; Parley Plan in Doubt

WASHINGTON (U.S.A.), April 12. (U.S.A.)—Franklin D. Roosevelt, President for 32 of the 44 years since the country's history, died at 1:05 p.m. (U.S.A.) today. He was in a room in the "White House" here.

Mr. Roosevelt had been in White Springs, which he had to call his "second home" since March 19. The week preceding he had spent at his home in Hyde Park, N.Y.


# Framingham, MA



- By the 1940's CVD was the number cause of death of Americans
  - Accounting for 50% of deaths
  - *and they didn't know why*
- Chosen b/c close to Harvard Cardiologists, physicians in town were keen, and represented an 'ideal' population of Americans
- Sept 29, 1948 - first patient screened



# 1957 – SBP identified as risk factor for CHD



Prevailing wisdom at the time thought that 'normal' BP was  $100 + \text{Age}$





# So what has Framingham taught us

## Framingham Risk Score<sup>1</sup>

### Atrial Fibrillation as an Independent Risk

Journal of the American College of Cardiology  
© 1999 by the American College of Cardiology  
Published by Elsevier Science Inc.

Vol. 33, No. 7, 1999  
ISSN 0735-1097/99/\$20.00  
DOI: 10.1016/S0735-1097(99)00118-7

## Congestive Heart Failure in Subjects With Normal Versus Obesity and the Risk of New-Onset Atrial Fibrillation

Ralph B. D'Agostino, Sr, PhD

Thomas J. Wang, MD

Helen Parise, ScD

Daniel Levy, MD

Ralph B. D'Agostino, Sr, PhD

Philip A. Wolf, MD

Ramachandran S. Vasan, MD

Emelia J. Benjamin, MD, ScM

**Context** Obesity is associated with a higher risk of heart failure, both known predictors of atrial fibrillation (AF). Obesity is a risk factor for AF.

**Objective** To examine the association of obesity with the risk of developing AF.

**Design, Setting, and Participants** A cohort study in Framingham, Mass. We studied 2,898 women (55%) without AF at baseline. Body mass index (calculated as weight in kilograms divided by square of height in meters)

was more accurate than in mortality studies.

#### Panel: Criteria for heart failure

##### Major

- Paroxysmal nocturnal dyspnoea or orthopnoea
- Neck-vein distension (not counting supine position)
- Rales in presence of unexplained dyspnoea
- Cardiomegaly and pulmonary hilar congestion (diagnosed by radiograph in absence of left-to-right shunt), or increasing heart size
- Acute pulmonary oedema described in hospital records
- Ventricular gallop
- Increased venous pressure ( $>16$  cm H<sub>2</sub>O from right atrium)
- Circulation time ( $>24$  s from arm to tongue)
- Hepato-jugular reflux
- Weight loss ( $\geq 4.5$  kg) in 5 days, due to therapy for heart failure

##### Minor

- Ankle oedema
- Night cough
- Dyspnoea on ordinary exertion
- Hepatomegaly
- Pleural effusion
- Decreased vital capacity by a third from maximum records
- Tachycardia ( $\geq 120$  beats per min)
- Weight loss ( $\geq 4.5$  kg) in 5 days, not related to therapy for heart failure

# Risk Factors – Can you name 10

## Non-Modifiable

- Age (↑)
- Gender (Male)
- Ethnicity (First Nations, South East Asian)
- Genetics
- Family History
  - 1st degree male <55 years or 1st degree female <65 years

## Modifiable

- Hypertension
- Diabetes
- Dyslipidaemia
- Smoking
- Physical Inactivity
- Obesity and Abdominal Girth
- Psychosocial
- Alcohol Consumption

# Calculating risk

## Low risk

5-9% MI or CHD  
death over next 10 years

## Moderate risk

10-19% risk

## High risk

≥20% risk



*May Require further risk  
stratification*

### Framingham Risk Score<sup>1</sup>

Risk assessment tool for estimating a patient's 10-year risk of developing cardiovascular disease

Age:	<input type="text"/> Years
Gender:	<input type="radio"/> Female <input type="radio"/> Male
Total cholesterol:	<input type="text"/> mmol/L
HDL cholesterol:	<input type="text"/> mmol/L
Smoker:	<input type="radio"/> Yes <input type="radio"/> No
Diabetes:	<input type="radio"/> Yes <input type="radio"/> No
Systolic blood pressure:	<input type="text"/> mm Hg
Is the patient being treated for high blood pressure?	<input type="radio"/> Yes <input type="radio"/> No

This online assessment tool is intended as a clinical practice aid for use by experienced healthcare professionals. Results obtained from this tool should not be used alone as a guide for patient care.

Calculate risk



# What is the 10-year risk of a 60 year old man with normal lipids, non-smoker, not HTNive

- A – 5%
- B – 10%
- C – 15%
- D – 20%




SPORTSCARDIOLOGYBC

# What is the 10-year risk of a 60 year old man with normal lipids, non-smoker, not HTNive

- A – 5%
- **B – 10%**
- C – 15%
- D – 20%

Age:	<input type="text" value="60"/> Years
Gender:	<input type="radio"/> Female <input checked="" type="radio"/> Male
Total cholesterol:	<input type="text" value="4"/> mmol/L
HDL cholesterol:	<input type="text" value="1.25"/> mmol/L
Smoker:	<input type="radio"/> Yes <input checked="" type="radio"/> No
Diabetes:	<input type="radio"/> Yes <input checked="" type="radio"/> No
Systolic blood pressure:	<input type="text" value="120"/> mm Hg
Is the patient being treated for high blood pressure?	<input type="radio"/> Yes <input checked="" type="radio"/> No

Calculate risk 



# What is the 10-year risk of a 60 year old man with normal lipids, non-smoker, not HTNive

- A – 5%
- **B – 10%**
- C – 15%
- D – 20%

## Framingham Risk Score - RESULTS<sup>1,4</sup>

Your patient's Framingham Risk Score is **11.2%**

### 2009 CCS Canadian Cholesterol Guidelines Recommendation<sup>1</sup>

Risk Level	Initiate/consider treatment if any of the following:	Primary LDL-C targets
<b>Moderate<sup>†</sup></b> (FRS 10-19%)	<ul style="list-style-type: none"><li>• LDL-C &gt; 3.5 mmol/L</li><li>• T C:HDL-C ratio of &gt; 5.0</li><li>• hsCRP &gt; 2 mg/L (in men &gt; 50 and women &gt; 60)<sup>‡</sup></li></ul>	<p>Either:</p> <ul style="list-style-type: none"><li>• &lt; 2.0 mmol/L or</li><li>• ≥ 50% reduction</li></ul>



SPORTSCARDIOLOGYBC



# What if that same patient is now 70

Age:	70 Years
Gender:	<input type="radio"/> Female <input checked="" type="radio"/> Male
Total cholesterol:	4 mmol/L
HDL cholesterol:	1.25 mmol/L
Smoker:	<input type="radio"/> Yes <input checked="" type="radio"/> No
Diabetes:	<input type="radio"/> Yes <input checked="" type="radio"/> No
Systolic blood pressure:	120 mm Hg
Is the patient being treated for high blood pressure?	<input type="radio"/> Yes <input checked="" type="radio"/> No

[Calculate risk](#)

## Framingham Risk Score - RESULTS<sup>1,4</sup>

Your patient's Framingham Risk Score is **18.4%**

### 2009 CCS Canadian Cholesterol Guidelines Recommendation<sup>1</sup>

Risk Level	Initiate/consider treatment if any of the following:	Primary LDL-C targets
<b>Moderate<sup>†</sup></b> (FRS 10-19%)	<ul style="list-style-type: none"> <li>LDL-C &gt; 3.5 mmol/L</li> <li>T C:HDL-C ratio of &gt; 5.0</li> <li>hsCRP &gt; 2 mg/L (in men &gt; 50 and women &gt; 60)<sup>‡</sup></li> </ul>	Either: <ul style="list-style-type: none"> <li>&lt; 2.0 mmol/L or</li> <li>≥ 50% reduction</li> </ul>



SPORTSCARDIOLOGYBC



# T/F – you should double a persons FRS 10-year risk if they have a FHx of premature CAD?


- TRUE

in first-degree relatives) increases an individual's calculated Framingham percent risk by approximately 2-fold.<sup>30</sup> The 10-year Framingham risk percent doubled for family history of premature CVD will be referred to as the modified FRS.






# Risk Stratification



# Intermediate Risk



SPORTSCARDIOLOGYBC



# Secondary Testing



SPORTSCARDIOLOGYBC

- Meant to aid clinicians in decision making for starting statin therapy
- Emerging evidence however suggests a more liberal approach to statin use
  - Especially in those with above low risk or moderate risk (5-19%)

# Secondary Testing



SPORTSCARDIOLOGYBC

- NOT performed for low (<5%) or high risk (>20%) patients
- Biomarkers
  - **Lipoprotein (a):**
    - LDL-like particle
    - Genetic link
    - Proatherogenic
    - Increased risk with > 300mg/L concentrations
  - **hsCRP**
    - not causally related to CVD risk, NOT target for Tx
    - Inflammatory marker
    - CRP>2.0mg/L (HR 1.5 for CVD)



# Biomarkers

- **HbA1c**

- Relationship with HbA1c and CVD risk in non-diabetics
- Each 1% increase in A1c above 5% had RR1.24

- **ACR**

- Albuminuria associated with hypertension and diabetes (risk factor for CVD)

# Secondary Testing



SPORTSCARDIOLOGYBC

Noninvasive test	Indications for testing	Normal Range		Frequency of testing
Graded exercise stress test	Selected asymptomatic adults with CVD risk factors especially those who are embarking on a vigorous exercise program Selected adults in the intermediate risk category	Low risk Moderate risk High risk	Duke Score <sup>a</sup> ≥ +5 -10 to +4 ≤ -11	If symptoms develop
Carotid imaging	Selected asymptomatic adults not candidates for statin Rx based on conventional risk factors. Only in centres with clear expertise	Carotid intima-media thickness (CIMT) <1.0 mm No visible plaque <sup>b</sup>		q 5-10 y as indicated for reassessment of risk
ABI	Selected asymptomatic adults, not candidates for statin Rx based on conventional risk factors (particularly smokers, diabetes)	Ankle-brachial index (ABI) 1.0-1.3 <sup>c</sup>		q 5-10 y as indicated for reassessment of risk or if symptoms develop
CAC	Selected asymptomatic adults who are not candidates for statin Rx based on conventional risk factors	Low risk Increased risk High risk Very high risk	CAC 0 0 – 99 100-299 <sup>d</sup> > 300 <sup>e</sup>	CAC = 0 q 10y where clinically indicated CAC = 0 – 100 q 3-5y if Rx is deferred

# Name 4 Non-pharm strategies to lower cholesterol

Intervention (minimal dose for effect)	Expected Outcome
Dietary cholesterol intake <sup>10</sup> < 300 mg/day (NCEP step I diet) < 200 mg/day (NCEP step II diet)	↓ LDL-C 10-12% 12-16%
Saturated fats <7% of daily caloric intake <sup>8</sup>	↓ LDL-C 5-10%; ↓ CVD mortality 14%
Phytosterols 1-2 gm/day <sup>1</sup>	↓ LDL-C 5-8%
Soy proteins with isoflavones 25g/day <sup>2</sup>	↓ LDL-C 3-5%
Viscous fibre 10 g/day <sup>3</sup>	↓ LDL-C 3-5%
Nuts 30-67g /day <sup>4</sup>	↓ LDL-C 5-7%, ↓ TG 5-10%
Portfolio type diet <sup>5</sup>	↓ LDL-C 8-14%
Mediterranean type diet <sup>6</sup>	↓ LDL-C 5-10%; ↓ CVD mortality
DASH (Dietary Approaches to Stop Hypertension) diet <sup>7</sup>	↓ CVD mortality in those with hypertension
Moderated Alcohol intake 1-2 drinks/day	↑ HDL 5-10%, ↓ CVD events
Weight loss and reduction of abdominal obesity <sup>11</sup> 5-10% of body weight loss	↓ LDL-C, ↑ HDL, ↓ TG, ↓ cardiometabolic risk
Omega -3 - 2-4 g of eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA)/day	↓ TG 25-30% in those with ↑ TG
Exercise <sup>12,13</sup> 30-60 min/day moderate to vigorous intensity	↑ HDL 5-10%, ↓ CVD events
Smoking cessation	↑ HDL, ↓ CVD events



# Treatment and Targets



SPORTSCARDIOLOGYBC

Risk level	Initiate therapy if	Primary target LDL C	Alternate target
<b>High</b> FRS $\geq 20\%$	<b>Consider treatment in all</b> (Strong, High)	$\leq 2$ mmol/L or $\geq 50\%$ decrease in LDL-C (Strong, High)	<ul style="list-style-type: none"> <li>➤ Apo B <math>\leq 0.8</math> g/L</li> <li>➤ Non HDL-C <math>\leq 2.6</math> mmol/L (Strong, High)</li> </ul>
<b>Intermediate</b> FRS 10%-19%	<ul style="list-style-type: none"> <li>➤ LDL-C <math>\geq 3.5</math> mmol/L (Strong, Moderate)</li> <li>➤ For LDL-C <math>&lt; 3.5</math> consider if: Apo B <math>\geq 1.2</math> g/L or Non-HDL-C <math>\geq 4.3</math> mmol/L (Strong, Moderate)</li> </ul>	$\leq 2$ mmol/L or $\geq 50\%$ decrease in LDL-C (Strong, Moderate)	<ul style="list-style-type: none"> <li>➤ Apo B <math>\leq 0.8</math> mg/L</li> <li>➤ Non HDL-C <math>\leq 2.6</math> mmol/L (Strong, Moderate)</li> </ul>
<b>Low</b> FRS $< 10\%$	<ul style="list-style-type: none"> <li>➤ LDL-C <math>\geq 5.0</math> mmol/L</li> <li>➤ Familial hypercholesterolemia (Strong, Moderate)</li> </ul>	$\geq 50\%$ reduction in LDL-C (Strong, Moderate)	

## LDL $< 2.0$



SPORTSCARDIOLOGYBC

# INTERHEART

**Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study**

*Salim Yusuf, Steven Hawken, Stephanie Öunpuu, Tony Dans, Alvaro Avezum, Fernando Lanas, Matthew McQueen, Andrzej Budaj, Prem Pais, John Varigos, Liu Lisheng, on behalf of the INTERHEART Study Investigators\**

- CASE CONTROL STUDY looking at RF for CAD
  - 14820 healthy control subjects
  - 15152 first-MI patients
- Conducted in 52 countries
- **9** risk factors are associated with more than **90%** of the risk of an acute myocardial infarction



# INTERHEART Risk Factors




SPORTSCARDIOLOGYBC

Risk factor	Prevalence		Odds ratio (99% CI) adjusted for age, sex, and smoking (OR 1)	PAR (99% CI)
	Controls (%)	Cases (%)		
Current smoking*	26.76	45.17	2.95 (2.72–3.20)	–
Current and former smoking*	48.12	65.19	2.27 (2.11–2.44)	36.4% (33.9–39.0)
Diabetes	7.52	18.45	3.08 (2.77–3.42)	12.3% (11.2–13.5)
Hypertension	21.91	39.02	2.48 (2.30–2.68)	23.4% (21.7–25.1)
Abdominal obesity (2 vs 1)†	33.40	30.21	1.36 (1.24–1.48)	–
Abdominal obesity (3 vs 1)†	33.32	46.31	2.24 (2.06–2.45)	33.7% (30.2–37.4)
All psychosocial‡	–	–	2.51 (2.15–2.93)	28.8% (22.6–35.8)
Vegetables and fruit daily*	42.36	35.79	0.70 (0.64–0.77)	12.9% (10.0–16.6)
Exercise*	19.28	14.27	0.72 (0.65–0.79)	25.5% (20.1–31.8)
Alcohol intake*	24.45	24.01	0.79 (0.73–0.86)	13.9% (9.3–20.2)
ApoB/ApoA1 ratio (2 vs 1)§	19.99	14.26	1.47 (1.28–1.68)	–
ApoB/ApoA1 ratio (3 vs 1)§	20.02	18.05	2.00 (1.74–2.29)	–
ApoB/ApoA1 ratio (4 vs 1)§	19.99	24.22	2.72 (2.38–3.10)	–
ApoB/ApoA1 ratio (5 vs 1)§	20.00	33.49	3.87 (3.39–4.42)	54.1% (49.6–58.6)
All above risk factors combined¶	–	–	129.20 (90.24–184.99)	90.4% (88.1–92.4)





# INTERHEART – cumulative risk



# Lipids



SPORTSCARDIOLOGYBC



# T/F - For every 1mmol of LDL lowering there is a 20% reduction in CV events



SPORTSCARDIOLOGYBC

- True!

**The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials**

*Cholesterol Treatment Trialists' (CTT) Collaborators\**


## **Summary**

**Background** Statins reduce LDL cholesterol and prevent vascular events, but their net effects in people at low risk of vascular events remain uncertain.

**Methods** This meta-analysis included individual participant data from 22 trials of statin versus control (n=134 537; mean LDL cholesterol difference 1·08 mmol/L; median follow-up 4·8 years) and five trials of more versus less statin (n=39 612; difference 0·51 mmol/L; 5·1 years). Major vascular events were major coronary events (ie, non-fatal myocardial infarction or coronary death), strokes, or coronary revascularisations. Participants were separated into five categories of baseline 5-year major vascular event risk on control therapy (no statin or low-intensity statin) (<5%, ≥5% to <10%, ≥10% to <20%, ≥20% to <30%, ≥30%); in each, the rate ratio (RR) per 1·0 mmol/L LDL cholesterol reduction was estimated.

**Findings** Reduction of LDL cholesterol with a statin reduced the risk of major vascular events (RR 0·79, 95% CI 0·77–0·81, per 1·0 mmol/L reduction), largely irrespective of age, sex, baseline LDL cholesterol or previous vascular disease, and of vascular and all-cause mortality. The proportional reduction in major vascular events was at

# Primary Prevention Trials



# What about statins for low risk patients? Do they work?

## **Statins for the primary prevention of cardiovascular disease (Review)**

Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K,  
Ebrahim S



SPORTSCARDIOLOGYBC

# Statins for Primary Prevention

- Over five years, the number needed to treat (NNT5) to avoid one cardiovascular event was 50
- The NNT5 for people at 10%, 20%, and 30% predicted cardiovascular event risk over 10 years were 74, 37, and 25 respectively
- These compare with NNT5 values of between 12 and 34 in secondary prevention





# Statins Primary Prevention

**Table 6** Outcome improvements with statin therapy in primary prevention found in the Cochrane review<sup>298</sup>


Outcome	Risk ratio (95% CI)
Total mortality	0.83 (0.73–0.95)
Fatal and nonfatal CHD events	0.72 (0.65–0.79)
Fatal and nonfatal stroke	0.78 (0.65–0.94)

38M. No past medical hx aside from erectile dysfunction. Should he have his lipids checked?

- YES!

### Who to Screen

Men  $\geq 40$  years of age, and women  $\geq 50$  years of age or postmenopausal  
(consider earlier in ethnic groups at increased risk such as South Asians or First Nations individuals)  
or  
All patients with any of the following conditions, regardless of age:

- Current cigarette smoking
- Diabetes
- Arterial hypertension
- Family history of premature CVD
- Family history of hyperlipidemia
- Erectile dysfunction 
- Chronic kidney disease

- Inflammatory disease
- HIV infection
- Chronic obstructive pulmonary disease
- Clinical evidence of atherosclerosis or abdominal aneurysm
- Clinical manifestation of hyperlipidemia
- Obesity (body mass index  $> 27$ )



SPORTSCARDIOLOGYBC

# How to screen

Canadian Journal of Cardiology 29 (2013) 151–167

## Society Guidelines

### 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

Todd J. Anderson, MD,<sup>a</sup> Jean Grégoire, MD,<sup>b</sup> Robert A. Hegele, MD,<sup>c</sup>

**For all: History and examination, LDL, HDL, TG, non-HDL (will be calculated from profile), glucose, eGFR**

**Optional: apoB (instead of standard lipid panel), urine albumin:creatinine ratio (if eGFR < 60, hypertension, diabetes)**

**Framingham Risk Score < 5%**

**Repeat every 3-5 years**


**Framingham Risk Score ≥ 5%**

**Repeat every year**

# How do statins work?



SPORTSCARDIOLOGYBC



# Don't Panic!



SPORTSCARDIOLOGYBC




**KEEP  
CALM**

**AND**

**DONT PANIC**

KeepCalmAndPosters.com



"The fuel light's on, Frank! We're all going to die! ...  
Wait, wait. ... Oh, my mistake—  
that's the intercom light."

# T/F – Simvastatin impairs adaptation to exercise?

- TRUE



SPORTSCARDIOLOGYBC





## **Simvastatin Impairs Exercise Training Adaptations**

Catherine R. Mikus, PhD,\* Leryn J. Boyle, MSc,† Sarah J. Borengasser,

- In sedentary adults (n=37) patients on simvastatin had lower increase in VO<sub>2</sub> than compared non-statin sedentary participants after 12 weeks
- Skeletal muscle citrate synthase activity increased by 13% in the exercise only group (P <0.05), but decreased by 4.5% in the simvastatin plus exercise group

# Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study



SPORTSCARDIOLOGYBC

Peter F Kokkinos, Charles Faselis, Jonathan Myers, Demosthenes Panagiotakos, Michael Doumas


	Deaths (n; %)	Unadjusted HR	Age-adjusted HR	Fully adjusted HR*	p value†
Least fit, statins (n=1060)	389 (37%)	1	1	1	..
Least fit, no statins (n=1024)	531 (52%)	1.22 (1.07-1.39)	1.22 (1.07-1.38)	1.35 (1.17-1.54)	<0.0001
Moderately fit, statins (n=1573)	329 (21%)	0.57 (0.49-0.66)	0.64 (0.56-0.75)	0.65 (0.56-0.75)	<0.0001
Moderately fit, no statins (n=1154)	397 (34%)	0.81 (0.70-0.93)	0.89 (0.77-1.02)	1.02 (0.88-1.12)	0.81
Fit, statins (n=1705)	173 (10%)	0.28 (0.23-0.33)	0.40 (0.33-0.48)	0.41 (0.34-0.49)	<0.0001
Fit, no statins (n=1335)	270 (20%)	0.50 (0.43-0.58)	0.69 (0.59-0.81)	0.81 (0.69-0.96)	0.01
Highly fit, statins (n=694)	39 (6%)	0.16 (0.12-0.22)	0.27 (0.19-0.38)	0.30 (0.21-0.41)	<0.0001
Highly fit, no statins (n=1498)	190 (13%)	0.27 (0.22-0.32)	0.42 (0.35-0.51)	0.53 (0.44-0.65)	<0.0001

# Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study



SPORTSCARDIOLOGYBC

Peter F Kokkinos, Charles Faselis, Jonathan Myers, Demosthenes Panagiotakos, Michael Doumas



# Smoking



SPORTSCARDIOLOGYBC





He's one of the busiest men in town. While his door may say *Office Hours 2 to 4*, he's actually on call 24 hours a day.

The doctor is a scientist, a diplomat, and a friendly sympathetic human being all in one, no matter how long and hard his schedule.

# NOT ONE SINGLE CASE OF THROAT IRRITATION *due to smoking* **CAMELS!**


Yes, these were the findings of noted throat specialists after a total of 2,470 weekly examinations of the throats of hundreds of men and women who smoked Camels—and only Camels—for 30 consecutive days.

## According to a recent Nationwide... **MORE DOCTORS SMOKED THAN ANY OTHER CIGARETTES**

**D**OCTORS in every branch of medicine—113,597 in all—were queried in this nationwide study of cigarette preference. Three leading research organizations made the survey. The gist of the query was—What cigarette do you smoke, Doctor?

*The brand named most was Camel!*

The rich, full flavor and cool mildness of Camel's superb blend of choice tobaccos seem to have the same appeal to the smoking tastes of doctors as to millions of other smokers. If you are a Camel smoker, this preference among doctors will hardly surprise you. If you're not—well, try Camels now.



*Start your own  
30-Day Camel  
MILDNESS  
Test Today!*

It's fun—it's enlightening! All you do is smoke Camels, and only Camels, for 30 days. Compare them to your "I love" (if you love, I fear, them). See if that rich, full Camel flavor and throat cool mildness doesn't win you to Camels for keeps.



BLANK O'BRIEN, real estate broker, one of the hundreds of people from coast to coast who made the 30-Day Test of Camel Mildness under the observation of noted throat specialists.

...AND THOUSANDS MORE AGREE!



**CAMELS SUITE** with me, Doctor, and they love me, too! says Ed Fenton, General Manager, who made the 30-day, coast-to-coast specialty.



**FEELING BETTER?** You're right, Doctor. "I don't believe any cigarette could make me feel like this. The Camels are the only other cigarette I've ever smoked."—Mildred Douglas, singer.



**I'M A DOCTOR** when it comes to smoking Camels. I've given the test of Camels to thousands of other doctors and always agree!—Mildred Douglas, singer.



**WIDE SMILE** accounts for my delight in Camels. The 30-day mildness test is something new to me.



**THE MILD TEST** was a real revelation. It taught me that there is no cigarette quite like a Camel!



**FEELING BETTER?** I'm a Doctor. I'll give you my word. I smoked Camels for 30 days. They were the best.

**CAMELS** Costlier Tobaccos





**SCIENCE**  
DISCOVERED IT —  
**YOU** CAN PROVE IT

**"No  
Unpleasant  
After-taste"**

— added to the world's most  
famous ABCs —

**A**lways Milder  
**B**etter Tasting  
**C**ooler Smoking

**Here's the Biggest 'Plus' in Cigarette History!**

"CHESTERFIELD IS THE ONLY CIGARETTE of all  
brands tested in which members of our taste  
panel found no unpleasant after-taste."

From the report of a well-known research organization

**A**lways **B**uy **C**CHESTERFIELD

Copyright 1964, Lorain & Weiss, Inc. N.Y.C.



SPORTSCARDIOLOGYBC



# Viceroy

***FILTER***  
**the Smoke!**





# Guard Against Throat-Scratch

enjoy the smooth smoking of fine tobaccos

... smoke **PALL MALL**  
the cigarette whose mildness  
you can measure



## Study This Puff Chart:

PUFF BY PUFF...YOU'RE ALWAYS AHEAD WITH PALL MALL



The further your cigarette filters the smoke through fine tobacco, the milder that smoke becomes. At the first puff, Pall Mall's smoke is filtered further than that of any other leading cigarette.



Again after 5 puffs of each cigarette your own eyes can measure the extra length for extra mildness as the smoke of Pall Mall's traditionally fine tobacco is filtered further. Moreover, after 10 puffs of each cigarette...



...or 17 puffs, Pall Mall's greater length of fine tobacco still breeds the smoke further - filters the smoke and makes it mild. Thus Pall Mall gives you a smoothness, mildness and satisfaction no other cigarette offers you.

Wherever you go today, you will see more and more people smoking PALL MALL - the cigarette whose mildness you can measure.

Outstanding  
...and they are mild!



P.S. LET A CARTON OF PALL MALLS SAY "MERRY CHRISTMAS" FOR YOU

Gee, Dad, you always get  
the best of everything  
...even

# Marlboro!



Yes, you need  
never feel  
over-smoked  
... that's the  
Miracle of  
Marlboro!





# T/F – 1 in 5 Canadians smoke



# T/F – 1 Billion people in the world smoke



## TRUE!!!

Shafey O, : The Tobacco Atlas,  
3rd ed. Atlanta, American Cancer  
Society, 2009.



# Tobacco Use




SPORTSCARDIOLOGYBC

- Single most important modifiable risk factor
  - >400,000 deaths annually
  - 35-40% of these are related to CAD
- Cessation of cigarette consumption overwhelmingly remains the single most important intervention in preventive cardiology...
  - more effective than any other secondary prevention strategy



# Cigarette smoking cessation: Risk of Non-fatal Myocardial Infarction\*




\*Includes those with known coronary heart disease

Critchley JA et al. *JAMA* 2003;290:86-97



# Risk of MI is the same in people who smoke 5 vs 25 cigarettes

- FALSE!



Number of controls	7489	727	1031	446	1058	96	230	168	56
Number of cases	4223	469	1021	623	1832	254	538	459	218
Odds ratio	1	1.38	2.10	2.99	3.83	5.80	5.26	6.34	9.16




SPORTSCARDIOLOGYBC

# Quitters never win?



SPORTSCARDIOLOGYBC

- Reduced coronary heart disease mortality by 36%
- Back to baseline risk at 2-3 years



\*Includes those with known coronary heart disease

Critchley JA et al. *JAMA* 2003;290:86-97

T/F – Smoking then Cholesterol are  
the biggest risk factors for stroke

## LEARN THE SIGNS OF STROKE

**F**ACE is it drooping?  
**A**RM**S** can you raise both?  
**S**PEECH is it slurred or jumbled?  
**T**IME to call 9-1-1 right away.



SPORTSCARDIOLOGYBC

# **Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study**

- hypertension - OR 2.64
- current smoking – OR 2.09
- waist-to-hip ratio – OR 1.65
- diet risk – OR 1.35
- regular physical activity – OR 0.69
- diabetes mellitus – OR 1.36
- alcohol intake OR - 1.51
- psychosocial stress OR- 1.30,
- ratio of apo B to A1 OR - 1.89
- Collectively, these risk factors accounted for 88.1% of the PAR for all stroke



SPORTSCARDIOLOGYBC

# Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study

- **hypertension - OR 2.64**
- **current smoking – OR 2.09**
- waist-to-hip ratio – OR 1.65
- diet risk – OR 1.35
- regular physical activity – OR 0.69
- diabetes mellitus – OR 1.36
- alcohol intake OR - 1.51
- psychosocial stress OR- 1.30,
- **ratio of apo B to A1 OR - 1.89**
- Collectively, these risk factors accounted for 88.1% of the PAR for all stroke.



SPORTSCARDIOLOGYBC







# Hypertension



SPORTSCARDIOLOGYBC



# Prevalence of HTN in Canada

21.8%

Number of Canadian  
adults 18+ suffering  
from hypertension

3.3%\*

of those age  
18 to 39

21.8%

of those age  
40 to 59

52.4%

of those age  
60 to 70

**...have hypertension.**

T/F – the target home BP is 140/90

**FALSE!**

Daytime  $>135/85$  = HTN

24 hour  $>130/80$  = HTN



SPORTSCARDIOLOGYBC

# Health Behaviours in Adults with Hypertension: Summary



SPORTSCARDIOLOGYBC

## Intervention

## Target



Reduce foods with added sodium

→ 2000 mg /day

Weight loss

BMI <25 kg/m<sup>2</sup>

Alcohol restriction

≤ 2 drinks/day

Physical activity

30-60 minutes 4-7 days/week

Dietary patterns

DASH diet

Smoking cessation


Smoke free environment

Waist circumference

Men <102 cm

Women <88 cm

# Epidemiologic impact on mortality of blood pressure reduction in the population



Reduction in SBP (mmHg)	% Reduction in Mortality		
	Stroke	CHD	Total
2	-6	-4	-3
3	-8	-5	-4
5	-14	-9	-7

Adapted from Whelton, PK et al. *JAMA* 2002;288:1882-1888

# T/F – 90% of Canadians have other CV risks in addition to HTN

- TRUE! 90% of hypertensive Canadians have other cardiovascular risks
- So... you should screen for them... HOW?



SPORTSCARDIOLOGYBC



# CHEP: Routine Laboratory Tests


## Preliminary Investigations of patients with hypertension

1. Urinalysis
2. Blood chemistry (potassium, sodium and creatinine)
3. Fasting glucose **and/or glycated hemoglobin (A1c)**
4. Fasting total cholesterol and high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), triglycerides
5. Standard 12-leads ECG

Currently there is insufficient evidence to recommend routine testing of microalbuminuria in people with hypertension who do not have diabetes




# Does diet really matter?



# Lyon Diet Heart Study

605 patients following a MI randomized to a Mediterranean\* or Western\*\* diet for 4 years



A Mediterranean diet reduces CV events post MI (secondary prevention)

\*High in polyunsaturated fat and fiber,

\*\*High in saturated fat and low in fiber

# Can you prevent CVD with diet?

## *The* NEW ENGLAND JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

APRIL 4, 2013


VOL. 368 NO. 14

Primary Prevention of Cardiovascular Disease  
with a Mediterranean Diet



SPORTSCARDIOLOGYBC


# Predimed



**Referral to a dietitian is associated with improved lipid profile  
Holmes. Journal of the American Dietetic Association. 2005.**



# What % of your cholesterol comes from your diet?



# What % of your cholesterol comes from your diet?





SPORTSCARDIOLOGYBC


Intervention (minimal dose for effect)	Expected Outcome
Dietary cholesterol intake <sup>10</sup> < 300 mg/day (NCEP step I diet) < 200 mg/day (NCEP step II diet)	↓ LDL-C 10-12% 12-16%
Saturated fats <7% of daily caloric intake <sup>8</sup>	↓ LDL-C 5-10%; ↓ CVD mortality 14%
Phytosterols 1-2 gm/day <sup>1</sup>	↓ LDL-C 5-8%
Soy proteins with isoflavones 25g/day <sup>2</sup>	↓ LDL-C 3-5%
Viscous fibre 10 g/day <sup>3</sup>	↓ LDL-C 3-5%







## Evolution of Physical Activity



# Does physical inactivity kill bus drivers?

**CORONARY HEART-DISEASE AND  
PHYSICAL ACTIVITY OF WORK**  
**J. N. MORRIS**                      **J. A. HEADY**  
M.A. Glasg., M.R.C.P., D.P.H.      M.A. Oxf  
OF THE SOCIAL MEDICINE RESEARCH UNIT, MEDICAL RESEARCH  
COUNCIL



- Examined the onset of CAD in 31 000 male transport workers aged 35 to 65 years
- Their main objective, however, was to “seek for relations between the kind of work men do and the incidence among them of CAD.”
- They chose to examine the bus conductors, who climbed 500 to 750 steps per working day on average, and the drivers who sat 90% of the day



# Does physical inactivity kill bus drivers?

YES!!!!

CORONARY HEART-DISEASE AND  
PHYSICAL ACTIVITY OF WORK  
J. N. MORRIS                      J. A. HEADY  
M.A. Glasg., M.R.C.P., D.P.H.      M.A. Oxf'd  
OF THE SOCIAL MEDICINE RESEARCH UNIT, MEDICAL RESEARCH  
COUNCIL



The conductors who climbed stairs all day...

- less incidence of CAD
- developed CAD later on
- first presentation of CAD less likely to be fatal

They postulated that physically active work was protective... in 1953

# Does physical inactivity kill longshoremen?

**OF COURSE!!!!**



- Paffenbarger et al followed 3263 longshoremen for 16 years
- The most active group of cargo handlers, who expended over 1000 kcal more than other longshoremen, had CAD death rates significantly lower than their sedentary colleagues
- Benefits persisted when smoking, BMI and SBP were taken into account

# Exercise-based cardiac rehabilitation for coronary heart disease

Balraj S Heran<sup>2</sup>, Jenny MH Chen<sup>2</sup>, Shah Ebrahim<sup>3</sup>, Tiffany Moxham<sup>4</sup>, Neil Oldridge<sup>5</sup>, Karen Rees<sup>6</sup>, David R Thompson<sup>7</sup>, and Rod S Taylor<sup>1</sup>

Copyright © 2011 The Cochrane Collaboration.

- All-cause mortality decreased by 13%
- Cardiovascular mortality decreased by 26%
- Hospital admissions decreased by 31%



SPORTSCARDIOLOGYBC

# Cardiac Risk Factors and Athletes





# Athletes are special



SPORTSCARDIOLOGYBC





# Athletes are special



SPORTSCARDIOLOGYBC



# T/F— Risk factor modification is not as important in athletes as the general population


- TRUE!!!
- FALSE!!!
- We don't really know



# Who would you treat aggressively?



# Who would you treat aggressively?



- 67F
- TC – 6; LDL – 4; HDL – 1.5
- Non-smoker
- SBP 156
- Vegan
- Runs 150km/wk
- Marathon 2:45:33
- Wealthy widow



- 45M
- TC – 5; LDL – 3.4; HDL – 1.2
- Smoker
- SBP 150
- Orders extra pickles at McD's
- Last exercised in high school
- Recently lost his job as bus driver





# Framingham Risk Score

## Framingham Risk Score<sup>1</sup>

Risk assessment tool for estimating a patient's 10-year risk of developing cardiovascular disease

Age:	<input type="text" value="67"/> Years
Gender:	<input checked="" type="radio"/> Female <input type="radio"/> Male
Total cholesterol:	<input type="text" value="6"/> mmol/L
HDL cholesterol:	<input type="text" value="1.5"/> mmol/L
Smoker:	<input type="radio"/> Yes <input checked="" type="radio"/> No
Diabetes:	<input type="radio"/> Yes <input checked="" type="radio"/> No
Systolic blood pressure:	<input type="text" value="156"/> mm Hg
Is the patient being treated for high blood pressure?	<input type="radio"/> Yes <input checked="" type="radio"/> No

This online assessment tool is intended as a clinical practice aid for use by experienced healthcare professionals. Results obtained from this tool should not be used alone as a guide for patient care.

Calculate risk







# Framingham Risk Score

## Framingham Risk Score - RESULTS<sup>1,4</sup>

**Your patient's Framingham Risk Score is** **15.9%**

### 2009 CCS Canadian Cholesterol Guidelines Recommendation<sup>1</sup>

Risk Level	Initiate/consider treatment if any of the following:	Primary LDL-C targets
<b>Moderate<sup>†</sup></b> (FRS 10-19%)	<ul style="list-style-type: none"><li>• LDL-C &gt; 3.5 mmol/L</li><li>• T C:HDL-C ratio of &gt; 5.0</li><li>• hsCRP &gt; 2 mg/L (in men &gt; 50 and women &gt; 60)<sup>‡</sup></li></ul>	<p>Either:</p> <ul style="list-style-type: none"><li>• &lt; 2.0 mmol/L or</li><li>• ≥ 50% reduction</li></ul>

Adapted from Genest et al. *Can J Cardiol.* 2009.<sup>1</sup>

<sup>†</sup> The assessment of moderate risk is further modulated by family history and hsCRP risk factors (RRS).

In moderate risk patients, lifestyle changes should be implemented first followed by medications if the targets are not reached. Please consult guidelines for complete recommendations

**Print results**





# Framingham Risk Score

## Framingham Risk Score<sup>1</sup>

Risk assessment tool for estimating a patient's 10-year risk of developing cardiovascular disease

Age:	<input type="text" value="45"/> Years
Gender:	<input checked="" type="radio"/> Female <input type="radio"/> Male
Total cholesterol:	<input type="text" value="5"/> mmol/L
HDL cholesterol:	<input type="text" value="1.2"/> mmol/L
Smoker:	<input checked="" type="radio"/> Yes <input type="radio"/> No
Diabetes:	<input type="radio"/> Yes <input checked="" type="radio"/> No
Systolic blood pressure:	<input type="text" value="150"/> mm Hg
Is the patient being treated for high blood pressure?	<input type="radio"/> Yes <input checked="" type="radio"/> No

This online assessment tool is intended as a clinical practice aid for use by experienced healthcare professionals. Results obtained from this tool should not be used alone as a guide for patient care.

Calculate risk





# Framingham Risk Score

## Framingham Risk Score - RESULTS<sup>1,4</sup>


**Your patient's Framingham Risk Score is** **11.7%**

### 2009 CCS Canadian Cholesterol Guidelines Recommendation<sup>1</sup>

Risk Level	Initiate/consider treatment if any of the following:	Primary LDL-C targets
<b>Moderate<sup>†</sup></b> (FRS 10-19%)	<ul style="list-style-type: none"><li>• LDL-C &gt; 3.5 mmol/L</li><li>• T C:HDL-C ratio of &gt; 5.0</li><li>• hsCRP &gt; 2 mg/L (in men &gt; 50 and women &gt; 60)<sup>‡</sup></li></ul>	<p>Either:</p> <ul style="list-style-type: none"><li>• &lt; 2.0 mmol/L or</li><li>• ≥ 50% reduction</li></ul>

Adapted from Genest et al. *Can J Cardiol.* 2009.<sup>1</sup>

# Who would put on a statin?



- **How can we treat her?**

- More exercise?
- Better diet?
- Lipitor 20mg
- Norvasc 5mg




- **How can we treat him?**

- Stop smoking
- Stop smoking
- Exercise (how much?)
- Mediterranean diet
- Employment
- Stop smoking

# Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study


Chi Pang Wen\*, Jackson Pui Man Wai\*, Min Kuang Tsai, Yi Chen Yang, Ting Yuan David Cheng, Meng-Chih Lee, Hui Ting Chan, Chwen Keng Tsao, Shan Pou Tsai, Xifeng Wu



- 15 minutes a day experienced a 14% reduced risk of all-cause mortality, and had a 3-year longer life expectancy.
- For every additional 15 minutes of daily further reduced all-cause mortality by 4% and all-cancer mortality by 1%



# Coronary Calcium Scan



# Who has more calcium in their coronary arteries?



# Running: the risk of coronary events<sup>†</sup>

## Prevalence and prognostic relevance of coronary atherosclerosis in marathon runners

**Stefan Möhlenkamp<sup>1\*</sup>, Nils Lehmann<sup>2</sup>, Frank Breuckmann<sup>1</sup>,**

- 108 apparently healthy male marathon runners aged >50 years, with >5 marathon were compared to age and cardiovascular risk matched controls
- Marathon runners had more calcium in their arteries compared with controls (36 vs. 21%)

# Prevalence of Subclinical Coronary Artery Disease in Middle-Aged, Male Marathon Runners Detected by Cardiac CT

## Prävalenz subklinischer koronarer Herzkrankheit bei männlichen Marathonläufern mittleren Alters: Detektion mittels koronarer CT-Angiografie

### Authors

I. Tsiflikas<sup>1</sup>, C. Thomas<sup>1</sup>, C. Fallmann<sup>2</sup>, C. Schabel<sup>1</sup>, S. Mangold<sup>1</sup>, D. Ketelsen<sup>1</sup>, C. D. Claussen<sup>1</sup>, D. Axmann<sup>3</sup>, S. Schroeder<sup>4</sup>, C. Burgstahler<sup>3</sup>

- 50 Male marathon runners (mean age 52.7)
- Avg 13.7 marathons completed
- CAD was detected in 24/50 runners:
  - 1 had significant CAD (>75%)
  - 3 had moderate CAD (50-75%)
  - 20 had mild CAD (<50%)



SPORTSCARDIOLOGYBC

# Possible Mechanisms



SPORTSCARDIOLOGYBC

- Shearing forces within coronary arteries during high heart rates
- Elevated circulating interleukins due to inflammation
- Production of free radicals were implicated as possible factors
- Increased sustained levels of catecholamines



# Another explanation?



SPORTSCARDIOLOGYBC



# Exercise and bad habits



# T/F – NCAA football players have a low incidence (<5%) of HTN

## Original Article

### High Prevalence of Hypertension Among Collegiate Football Athletes

Ashley Rowatt Karpinos, MD, MPH; Christianne L. Roumie, MD, MPH; Hui Nian, PhD, MS;  
Alex B. Diamond, DO, MPH; Russell L. Rothman, MD, MPP

- NCAA athletes seen at pre-participation screening
  - 19.2% of football athletes had hypertension and 61.9% had prehypertension
  - 7% of non-football athletes





# Even these type of footballers have hypertension




# What is Masked HTN?






# What is Masked HTN?



Derived from Pickering et al. *Hypertension* 2002;40:795-796

# The Prognosis of Masked Hypertension

**Prevalence is approximately 10% in hypertensive patients.**



# Endurance Athletes and Masked HTN

- Male participants of a 10-mile race were recruited and included if office blood pressure was normal ( $<140/90$  mmHg)
- Given ambulatory BP monitor
- mean age was  $42 \pm 8$
- 38% had masked hypertension
- Those with masked hypertension had worse diastolic function and more LVH



# Athletes are not special?

## Position Paper

### **ESC Study Group of Sports Cardiology Recommendations for participation in leisure-time physical activities and competitive sports for patients with hypertension**

Robert H. Fagard<sup>a</sup>, Hans H. Björnstad<sup>b</sup>, Mats Börjesson<sup>c</sup>, François Carré<sup>d</sup>, Asterios Deligiannis<sup>e</sup> and Luc Vanhees<sup>a,f</sup>

## **Recommendations**

### **General recommendations**

Athletes with hypertension should be treated according to the general guidelines for the management of

# Sports and Anti-HTN drugs

- **Beta-blockers** – lower HR, ↓MV02 by ~7%, banned in some sports
- **Diuretics** – risk of dehydration, electrolyte abnormalities, ↓MV02, banned by most sporting agencies (masking agent)
- **ACEi/ARB + DHP CCB** (amlodipine) are preferred anti-HTN in athletes – can cause excessive BP lowering post exercise





# WADA banned substances

**Table 1.** Categories of prohibited substances and methods (WADA 2012).<sup>9</sup>

**I. Substances and methods prohibited at all times (in- and out-of-competition)**

**A. Prohibited substances**

**S0. Non-approved substances<sup>1</sup>**

**S1. Anabolic agents:**

- Anabolic androgenic steroids
- Other anabolic agents

**S2. Peptide hormones, growth factors, and related substances<sup>2</sup>**

**S3. Beta-2 agonists**

**S4. Hormone and metabolic modulators<sup>3</sup>**

**S5. Diuretics and other masking agents**

**B. Prohibited methods**

**M1. Manipulation of blood and blood components**

**M2. Chemical and physical manipulation**

**M3. Gene doping**

**II. Substances and methods prohibited in-competition**

**S6. Stimulants**

**S7. Narcotics**

**S8. Cannabinoids**

**S9. Glucocorticosteroids**

**III. Substances prohibited in particular sports**

**P1. Alcohol<sup>4</sup>**

**P2. Beta-blockers<sup>5</sup>**



SPORTSCARDIOLOGYBC

# HTN Guidelines for athletes

## **AHA/ACC SCIENTIFIC STATEMENT**

# **Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension**

A Scientific Statement from the American Heart Association and the American College of Cardiology

# HTN Guidelines



SPORTSCARDIOLOGYBC

- 3. Those with prehypertension (BP of 120/80 mm Hg-139/89 mm Hg) should be encouraged to modify their lifestyles but **should not** be restricted from physical activity. Those with sustained hypertension should have screening echocardiography performed. Athletes with LVH beyond that seen with “athlete’s heart” should limit participation until BP is normalized by appropriate antihypertensive drug therapy (*Class IIa; Level of Evidence B*).**

# HTN Guidelines



SPORTSCARDIOLOGYBC

- 4. It is reasonable that athletes with stage 2 hypertension (a systolic BP  $>160$  mm Hg or a diastolic BP  $>100$  mm Hg), even without evidence of target-organ damage, should be restricted, particularly from high static sports, such as weight lifting, boxing, and wrestling, until hypertension is controlled by either lifestyle modification or drug therapy (*Class IIa; Level of Evidence B*).**



# Guideline recommendations of athletes with KNOWN CAD

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY  
© 2015 BY THE AMERICAN HEART ASSOCIATION, INC. AND  
THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION  
PUBLISHED BY ELSEVIER INC.

VOL. ■, NO. ■, 2015  
ISSN 0735-1097/\$36.00  
<http://dx.doi.org/10.1016/j.jacc.2015.09.040>

## **AHA/ACC SCIENTIFIC STATEMENT**

# **Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease**

A Scientific Statement from the American Heart Association and American College of Cardiology



# Known CAD Recommendations

## Recommendations

- 1. Athletes with ASCAD should undergo maximal exercise testing to evaluate exercise tolerance, the presence of inducible ischemia, and the presence of exercise-induced electrical instability. Testing should be performed on the subject's standard medical regimen, including  $\beta$ -adrenergic blocking medications (*Class I; Level of Evidence C*).**
- 2. Athletes with ASCAD should undergo an evaluation of left ventricular function (*Class I; Level of Evidence C*).**

# Known CAD Recommendations



SPORTSCARDIOLOGYBC

4. Athletes with ASCAD should undergo aggressive risk factor reduction with high-intensity statin therapy to reduce the chance of plaque disruption (6) (Class I; Level of Evidence A).

# Known CAD Recommendations



SPORTSCARDIOLOGYBC

6. It is **reasonable** for patients with clinically manifest ASCAD to participate in all competitive activities if their resting left ventricular ejection fraction is **>50%**, they are **asymptomatic**, and they have no inducible **ischemia** or **electrical instability** (***Class IIb; Level of Evidence C***).


# Known CAD Recommendations

- 8. It is reasonable to prohibit patients with clinically manifest ASCAD from competitive sport participation:**
  - a. For at least 3 months after an AMI or coronary revascularization procedure (*Class IIb; Level of Evidence C*);**
  - b. If they have increasing frequency or worsening symptoms of myocardial ischemia (*Class IIb; Level of Evidence C*).**

# U-Shaped Curve?



SPORTSCARDIOLOGYBC





# Elite athletes




SPORTSCARDIOLOGYBC


- Elite athletes compared to controls:
  - LOWER rates of smoking
  - LOWER rates of CAD
  - LOWER rates of diabetes
  - LOWER rates of depression + anxiety
  - HIGHER rates of OA (but more likely to remain physically active)



# Survival of professional cyclists



# Do Olympians enjoy longer life?




**Figure 2** Survival of Olympic medallists, by country group. \*Excludes medallists from Olympic Games before 1950.


# Canadian Olympians and Mortality



SPORTSCARDIOLOGYBC



survival advantage over their matched compatriots. The survival advantage of Canadian medallists at 30 years over the general population was not significant (1.04, 0.99 to 1.08).





# Type of sport and disease specific mortality

All-cause and disease-specific mortality among male, former elite athletes: an average 50-year follow-up

Jyrki A Kettunen,<sup>1</sup> Urho M Kujala,<sup>2</sup> Jaakko Kaprio,<sup>3,4,5</sup> Heli Bäckmand,<sup>6</sup>

**Table 3** Disease-specific mortality HRs and their 95% CI in different sport groups compared to controls

Sports	Mortality HR† (95% CI)		
	Ischaemic heart disease (n=815)	Cancer (n=578)	Stroke (n=207)
Endurance sports	0.68 (0.54 to 0.86)*	0.62 (0.47 to 0.82)*	0.52 (0.33 to 0.83)*
Team sports	0.73 (0.60 to 0.89)*	0.72 (0.58 to 0.90)*	0.59 (0.40 to 0.88)*
Power sports	0.99 (0.83 to 1.18)	0.80 (0.64 to 1.00)	0.73 (0.51 to 1.05)
Controls	1	1	1

Elite athletes have 5–6 years additional life expectancy when compared to men who were healthy as young adults



# SCBC Masters Athlete Screening Study

- **Primary Objective:**
  - Prevent adverse cardiac events and sudden cardiac death in Masters athletes
- **Outcomes:**
  - Prevalence of cardiovascular disease (i.e. CAD)
  - Prevalence of risk factors (i.e. hypertension, dyslipidemia)
  - Prevalence of atrial fibrillation in the masters athlete and its association with intensity of sport and volume of physical activity



**N = 800+ Recreationally Competitive and High Performance Masters Athletes**

**Initial Screen:**

History and Personal Symptoms Questionnaire, Physical Exam,  
Framingham Risk Score, Resting 12-lead ECG

**Negative**

No Further Testing →  
Follow-up (5 Years):  
ECG, FRS,  
Questionnaire

**Positive**

**Exercise Treadmill Test**

**Negative: Follow-Up  
(5 years): ECG, FRS,  
Questionnaire**

**Positive**

**Further Examinations (i.e. echo, 24 h  
holter, CMR, CCT/CACS)**

**No Cardiovascular  
Disease**


**Follow-up (5 years):  
ECG, FRS,  
Questionnaire**

**CVD → q1yr Follow-up**

**Other →  
Clinical Care**

# Masters Study – Interim Results

## Framingham Risk Score




185  
Patients

# Masters Study – Interim Results




SPORTSCARDIOLOGYBC



# Masters Study – Interim Results



SPORTSCARDIOLOGYBC






# Masters Study – Interim Results



SPORTSCARDIOLOGYBC



# Masters Study – Interim Conclusions



SPORTSCARDIOLOGYBC

- Masters athletes are not immune to elevated cardiovascular risk
- Significant CV disease exists amongst asymptomatic physically fit Masters athletes
- Systematic screening amongst Masters athletes may be worthwhile in select cases
- To evaluate the incidence of symptomatic and asymptomatic cardiovascular disease over 5 years



# Conclusions

- Athletes are special
  - in *most cases* athletes live longer than their sedentary counterparts
- However, athletes can still have elevated cardiovascular risk and risk factors that should be treated as per general guideline recommendations

# SportsCardiologyBC



Stay active, stay fit, stay safe

<http://www.sportscardiologymbc.org/>

## OUR MISSION

### Clinical Assessment

With the overwhelming existing evidence of the beneficial and preventive effects of exercise, our society is becoming more and more physically active. Our goal is to assess and evaluate athletes to ensure safe participation in athletics.



### Research

With an aging population and an overall increase in the participation of regular athletics and exercise in the general population, research in risk factors and warning signs for cardiovascular events must be investigated.



### Advocacy

In order to educate the public on the importance of cardiovascular health and help prevent tragic cardiovascular events, Sports Cardiology B.C. will collaborate with local, national and international organizations.



### Education

Through the dissemination of results from research investigation and the interpretation of clinical case studies, public education on safe participation in athletics needs to be provided.

